BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) shares traded down 2.4% on Monday . The company traded as low as C$17.16 and last traded at C$17.18. 4,057 shares were traded during mid-day trading, an increase of 60% from the average session volume of 2,529 shares. The stock had previously closed at C$17.60.
BriaCell Therapeutics Price Performance
The business’s fifty day simple moving average is C$12.40 and its two-hundred day simple moving average is C$32.00. The company has a market cap of C$30.15 million, a PE ratio of -0.22 and a beta of 3.12.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC).
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- FICO’s Big Dip Could Be the Best Buying Chance of the Year
- Consumer Staples Stocks, Explained
- D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Datavault: A Speculative AI Play, But Beware of Volatility
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
